Dr. Atanasio on Ibrutinib and Obinuzutumab Combination in CLL/SLL

Carolina Moreno Atanasio, MD
Published: Saturday, Jun 20, 2015



Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Treatment in older patients with CLL or SLL can be challenging due to likelihood of comorbidities, Atanasio says. Previous studies show that the combination of chlorambucil with obinutuzumab improved progression-free and overall survival in patients with comorbidities. However, it did not show a benefit in patients with poor prognosis or who had a 17p deletion.

The multicenter randomized phase III study comparing the combinations of ibrutinib and obinutuzumab with chlorambucil and obinutuzumab has not yet begun enrolling patients. Results of the study, Atanasio says, could potentially identify new treatments for patients who are ineligible for chemoimmunotherapy.

<<< View more from the 13th International Conference on Malignant Lymphoma



Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Treatment in older patients with CLL or SLL can be challenging due to likelihood of comorbidities, Atanasio says. Previous studies show that the combination of chlorambucil with obinutuzumab improved progression-free and overall survival in patients with comorbidities. However, it did not show a benefit in patients with poor prognosis or who had a 17p deletion.

The multicenter randomized phase III study comparing the combinations of ibrutinib and obinutuzumab with chlorambucil and obinutuzumab has not yet begun enrolling patients. Results of the study, Atanasio says, could potentially identify new treatments for patients who are ineligible for chemoimmunotherapy.

<<< View more from the 13th International Conference on Malignant Lymphoma


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x